Noven expands pipeline with $125M JDS buyout

Noven Pharmaceuticals is paying $125 million in cash and assuming $10 million in debt to clinch a deal to acquire New York-based JDS Pharmaceuticals. Noven, which makes drug patch products, bags two products on the market and a pipeline of experimental therapies for psychiatry and women's health. JDS's two approved drugs are Lithobid for bipolar disorder and Pexeva for depression. If all goes according to plan, Noven says the acquisition will add more than $500 million in new sales by 2012. JDS' co-founder Phillip Satow is set to join the board after the deal closes in August.

- see the release on the buyout
- check out the AP report on the buyout

Related Articles:
FDA rejects Noven's copycat version of Duragesic pain patch. Report
FDA approves Daytrana ADHD patch. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.